Thus, nuclear–cytoplasmic shuttling currently represents an attractive therapeutic target investigated in different tumor types [36], as recently demonstrated by the Food and Drug Administration approval of the exportin 1 inhibitor selinexor for multiple myeloma [29]. The gene discussed is XPO1; the disease is neoplasm.